These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 8328993)

  • 41. Anodic coulometric detection with a glassy carbon electrode in combination with reversed-phase high-performance liquid chromatography. Determination of blood levels of perphenazine and fluphenazine.
    Tjaden UR; Lankelma J; Poppe H
    J Chromatogr; 1976 Sep; 125(1):275-86. PubMed ID: 977680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Secondary effects of Moditen-Retard].
    Fouks L
    Encephale; 1970; ():Suppl:14-8. PubMed ID: 5458708
    [No Abstract]   [Full Text] [Related]  

  • 43. [Characteristics of the psychotropic activity of long-acting drugs (experience in the use of Moditen-depot)].
    Smulevich AB; Minsker EI; Mazaeva NA; Volkova RP; Lukanina SK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(6):912-20. PubMed ID: 5050051
    [No Abstract]   [Full Text] [Related]  

  • 44. The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.
    Midha KK; Hubbard JW; Marder SR; Hawes EM; Van Putten T; McKay G; May PR
    Psychopharmacology (Berl); 1987; 93(3):369-73. PubMed ID: 3124166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Depot fluphenazine enanthate and decanoate: comparative rates of release in dogs.
    Dreyfuss J; Ross JJ; Shaw JM; Miller I; Schreiber EC
    J Pharm Pharmacol; 1975 Oct; 27(10):791-2. PubMed ID: 241800
    [No Abstract]   [Full Text] [Related]  

  • 46. The use of fluphenazine decanoate (Modecate)depot therapy in outpatient schizophrenics-a retrospective study.
    Tan CT; Ong TC; Chee KT
    Singapore Med J; 1981 Aug; 22(4):214-8. PubMed ID: 7323829
    [No Abstract]   [Full Text] [Related]  

  • 47. Fluphenazine hydrochloride, enanthate, and decanoate in the management of chronic psychosis.
    Itil T; Keskiner A
    Dis Nerv Syst; 1970 Sep; 31():Suppl:37-42. PubMed ID: 4920313
    [No Abstract]   [Full Text] [Related]  

  • 48. Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia.
    Chang SS; Javaid JI; Dysken MW; Casper RC; Janicak PG; Davis JM
    Psychopharmacology (Berl); 1985; 87(1):55-8. PubMed ID: 3933037
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined intramuscular administration of depot fluphenazine and benztropinemesylate in chronic schizophrenic patients.
    Bucci L
    Curr Ther Res Clin Exp; 1971 Aug; 13(8):545-8. PubMed ID: 4999204
    [No Abstract]   [Full Text] [Related]  

  • 50. Determination of the metabolites of gestrinone in human urine by high performance liquid chromatography, liquid chromatography/mass spectrometry and gas chromatography/mass spectrometry.
    Kim Y; Lee Y; Kim M; Yim YH; Lee W
    Rapid Commun Mass Spectrom; 2000; 14(18):1717-26. PubMed ID: 10962496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Injection site leakage of depot neuroleptics: intramuscular versus subcutaneous injection.
    Glazer WM; Maynard C; Berkman CS
    J Clin Psychiatry; 1987 Jun; 48(6):237-9. PubMed ID: 3584079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection.
    Glazer WM; Friedhoff LT; Marder SR; Brown WA
    Schizophr Res; 1992 Dec; 8(2):111-7. PubMed ID: 1457388
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil.
    Luo JP; Hubbard JW; Midha KK
    Pharm Res; 1997 Aug; 14(8):1079-84. PubMed ID: 9279892
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An ultrasensitive method for the measurement of fluphenazine in plasma by high-performance liquid chromatography with coulometric detection.
    Cooper JK; Hawes EM; Hubbard JW; McKay G; Midha KK
    Ther Drug Monit; 1989; 11(3):354-60. PubMed ID: 2728094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients.
    Midha KK; Hawes EM; Hubbard JW; Korchinski ED; McKay G
    Psychopharmacology (Berl); 1988; 96(2):206-11. PubMed ID: 3148147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring.
    Allanson AL; Cotton MM; Tettey JN; Boyter AC
    J Pharm Biomed Anal; 2007 Aug; 44(4):963-9. PubMed ID: 17531423
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pharmacological studies of long-acting phenothiazines with particular reference to fluphenazine decanoate (author's transl)].
    Chen PC
    Nihon Yakurigaku Zasshi; 1978 Oct; 74(7):871-83. PubMed ID: 570538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Release and elimination of 14C-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs.
    Dreyfuss J; Ross JJ; Shaw JM; Miller I; Schreiber EC
    J Pharm Sci; 1976 Apr; 65(4):502-507. PubMed ID: 1271246
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pharmacist's role in team treatment of patients receiving injectable long-acting fluphenazine.
    Giles RE
    Hosp Pharm; 1976 Oct; 11(10):404, 407-8. PubMed ID: 1028808
    [No Abstract]   [Full Text] [Related]  

  • 60. A highly sensitive and specific radioimmunoassay for quantitation of plasma fluphenazine.
    Lo ES; Fein M; Hunter C; Suckow RF; Cooper TB
    J Pharm Sci; 1988 Mar; 77(3):255-8. PubMed ID: 3373431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.